Browsing by Author "Gulbas, Z."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
    (OXFORD UNIV PRESS, 2017-01-01) Bekoz, H.; Karadurmus, N.; Paydas, S.; Turker, A.; Toptas, T.; Tuglular, T. Firatli; Sonmez, M.; Gulbas, Z.; Tekgunduz, E.; Kaya, A. H.; Ozbalak, M.; Tastemir, N.; Kaynar, L.; Yildirim, R.; Karadogan, I.; Arat, M.; Tanrikulu, F. Pepedil; Ozkocaman, V.; Abali, H.; Turgut, M.; Yuksel, M. Kurt; Ozcan, M.; Dogu, M. H.; Hacioglu, S. Kabukcu; Barista, I.; Demirkaya, M.; Koseoglu, F. D.; Toprak, S. K.; Yilmaz, M.; Demirkurek, H. C.; Demirkol, O.; Ferhanoglu, B.
    Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years